Entering text into the input field will update the search result below

Premarket analyst action - healthcare

  • Deciphera Pharmaceuticals (NASDAQ:DCPH) initiated with Overweight rating and $30 (54% upside) price target by JPMorgan. Initiated with Overweight rating by Piper Jaffray. Initiated with Outperform rating by JMP Securities. Initiated with Buy rating by Nomura.
  • Bioverative (NASDAQ:BIVV) initiated with Overweight rating and $71 (18% upside) price target by Piper Jaffray.
  • AMAG Pharmaceuticals (NASDAQ:AMAG) initiated with Neutral rating and $18 (15% upside) price target by Piper Jaffray.
  • TESARO (NASDAQ:TSRO) initiated with Equal Weight rating and $135 (16% upside) price target by Barclays.
  • Nightstar Therapeutics (NASDAQ:NITE) initiated with Outperform rating by Wedbush and Outperform rating by BMO Capital Markets.
  • Celgene (NASDAQ:CELG) resumed with Neutral rating and $133 (10% upside) price target by Piper Jaffray.
  • NuCana (NASDAQ:NCNA) initiated with Buy rating and $25 (79% upside) by Jefferies. Initiated at Outperform by Cowen. Initiated with Buy rating by Citigroup with a $23 price target. Initiated with Outperform rating by William Blair.
  • GlycoMimetics (NASDAQ:GLYC) initiated with Buy rating by Roth Capital.
  • Syros Pharmaceuticals (NASDAQ:SYRS) initiated with Neutral rating and $15 (9% downside risk) price target by Roth Capital.
  • Clovis Oncology (NASDAQ:CLVS) initiated with Overweight rating and $105 (35% upside) price target by Barclays.
  • Omega Health (NYSE:OHI) initiated with Equal Weight rating and $34 (6% upside) price target by CapitalOne.
  • Biogen (NASDAQ:BIIB) resumed with Overweight rating and $390 (15% upside) price target by Piper Jaffray. Downgraded to Neutral by Citigroup.
  • Aptose Biosciences (NASDAQ:APTO) resumed with Buy rating and $5 (250% upside) by Roth Capital.
  • Alexion Pharmaceuticals (NASDAQ:ALXN) resumed with Overweight rating and $170 (22% upside) price target by Piper Jaffray.
  • Voyager Therapeutics (NASDAQ:VYGR) price target raised to $31 (34% upside) from $20 by Stifel citing upside of Parkinson's program. Sanofi/Genzyme expected to take ex-U.S. option to develop.
  • Athenahealth (NASDAQ:ATHN) upgraded to Equal Weight with $127 (1% upside) price target by First Analysis.
  • Sierra Oncology (NASDAQ:SRRA) upgraded to Buy by Jefferies.
  • Illumina (NASDAQ:ILMN) upgraded to Buy by Deutsche Bank. Upgraded to Neutral by Janney.
  • Ritter Pharmaceuticals (NASDAQ:RTTR) price target lowered to $1.50 (317% upside) by H.C. Wainwright.Antares Pharmaceuticals (NASDAQ:ATRS) price target lowered to $3.50 (61% upside) by H.C. Wainwright after FDA rejection of XYOSTED NDA.
  • MiMedx (OTC:MDXG) remains Underweight with suspended price target by First Analysis after management failed to address questions in multiple public calls while "sparring" with short sellers.
  • Source: Bloomberg

Recommended For You

About DCPH Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
DCPH--
Deciphera Pharmaceuticals, Inc.